IVMT

InVaMet Therapeutics is a pre-clinical stage biotechnology company dedicated to developing first-in-class small molecule inhibitors for the treatment of metastatic and invasive cancers. The company's proprietary platform focuses on targeting Melanoma Differentiation-Associated protein 9 (MDA-9/Syntenin), a scaffolding protein that serves as a critical molecular hub for cancer progression, angiogenesis, and immune evasion. By inhibiting the PDZ domains of MDA-9, InVaMet's lead candidates aim to disrupt the metastatic cascade and enhance the effectiveness of existing standard-of-care therapies. Founded by leading oncology researchers from Virginia Commonwealth University and the Sanford Burnham Prebys Medical Discovery Institute, the company is advancing a pipeline of targeted inhibitors for high-unmet-need indications, including melanoma, glioblastoma, and various solid tumors.